SCHEMBL6979095

SCHEMBL6979095

S=c1nc(-c2ccccc2Cl)[nH]n1CCc1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 19/20 0.78
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6980343 0.92 CXCR2 (0.74) CXCR2MEN1KMT2A
SCHEMBL6971493 0.89 CXCR2 (0.78) CXCR2
SCHEMBL6973157 0.87 CXCR2 (1.00) CXCR2
SCHEMBL6975307 0.87 CXCR2 (1.00) CXCR2
SCHEMBL7526169 0.78 CXCR2 (0.55) CXCR2MEN1KMT2A
SCHEMBL6976397 0.78 CXCR2 (1.00) CXCR2
SCHEMBL6981330 0.78 CXCR2 (1.00) CXCR2
SCHEMBL6976655 0.77 CXCR2 (0.80) CXCR2
SCHEMBL6968967 0.76 CXCR2 (0.78) CXCR2
SCHEMBL6979058 0.76 CXCR2 (0.82) CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109790-B1 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS ASTRAZENECA AB (SE) 2003-05-14 EP claimed
US-20020086862-A1 Novel compounds ASTRAZENECA AB 2002-07-04 US claimed
EP-1109790-B1 1, 2, 4-TRIAZOLE-3-THIONE COMPOUNDS ASTRAZENECA AB (SE) 2003-05-14 EP disclosed
US-20020086862-A1 Novel compounds ASTRAZENECA AB 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086862-A1 Novel compounds ABCG2, CYP3A4, CYP4B1 CXCR2 568/4885MEN1 2755/4885KMT2A 4259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.